Vaxart, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Vaxart, Inc. (VXRT) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$30.00 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2017-09-01
- Vaxart, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was $1.20M, a 9.09% increase year-over-year.
- Vaxart, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was -$11.50M.
- Vaxart, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-12-31 was -$9.00M.
- Vaxart, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-09-30 was -$10.70M, a 1288.89% decline year-over-year.
- Vaxart, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$30.00M.
- Vaxart, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$14.10M.
- Vaxart, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$9.60M.
- Vaxart, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$3.30M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01 | -$10.30M derived: sum of 2 quarters · filed 2017-09-01 | -$19.30M derived: sum of 3 quarters · filed 2017-09-01 | -$30.00M 10-K · filed 2017-09-01 |
| 2017-03-31 | -$11.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08 | -$20.50M derived: sum of 2 quarters · filed 2017-05-08 | -$31.20M 10-Q · filed 2017-05-08 | -$30.10M derived: sum of 4 quarters · filed 2017-09-01 |
| 2016-12-31 | -$9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-06 | -$19.70M 10-Q · filed 2017-02-06 | -$18.60M derived: sum of 3 quarters · filed 2017-09-01 | -$25.60M derived: sum of 4 quarters · filed 2017-09-01 |
| 2016-09-30 | -$10.70M 10-Q · filed 2016-11-08 | -$9.60M derived: sum of 2 quarters · filed 2017-09-01 | -$16.60M derived: sum of 3 quarters · filed 2017-09-01 | -$25.70M derived: sum of 4 quarters · filed 2017-09-01 |
| 2016-06-30 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01 | -$5.90M derived: sum of 2 quarters · filed 2017-09-01 | -$15.00M derived: sum of 3 quarters · filed 2017-09-01 | -$14.10M 10-K · filed 2017-09-01 |
| 2016-03-31 | -$7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08 | -$16.10M derived: sum of 2 quarters · filed 2017-05-08 | -$15.20M 10-Q · filed 2017-05-08 | |
| 2015-12-31 | -$9.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-06 | -$8.20M 10-Q · filed 2017-02-06 | ||
| 2015-09-30 | $900.00K 10-Q · filed 2016-11-08 | |||
| 2015-06-30 | -$9.60M 10-K · filed 2016-09-13 | |||
| 2014-06-30 | -$3.30M 10-K · filed 2016-09-13 | |||
| 2012-09-30 | -$5.59M 10-Q · filed 2012-11-08 | |||
| 2011-12-31 | -$5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | -$10.59M derived: sum of 2 quarters · filed 2012-03-14 | -$19.62M 10-K · filed 2012-03-14 | |
| 2011-09-24 | -$5.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | -$14.07M 10-Q · filed 2012-11-08 | ||
| 2011-06-25 | -$9.03M 10-Q · filed 2011-08-03 | |||
| 2010-12-25 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | -$489.00K derived: sum of 2 quarters · filed 2012-03-14 | $40.54M 10-K · filed 2012-03-14 | |
| 2010-09-25 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $42.09M 10-Q · filed 2011-11-02 | ||
| 2010-06-26 | $41.03M 10-Q · filed 2011-08-03 | |||
| 2009-12-26 | -$3.63M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |